Pharma's latest settlement with the Department of Justice involves a small-potatoes monetary penalty--only $33.5 million total--but it includes something most settlements haven't, at least so far. As part of the deal, ISTA Pharmaceuticals, a subsidiary of Bausch + Lomb, will be excluded from federally funded healthcare programs like Medicare and Medicaid.
Bausch & Lomb, which has been building its prescription drug business, is drawing enough attention from Big Pharma names such as Sanofi ($SNY) and Merck & Co. ($MRK) that its private equity investors may just sell it instead of going the IPO route.
Lupin executives keep talking up their plans for U.S. expansion. Buying brands, buying companies, pumping up its own launches of generic drugs--the Indian drugmaker says it's going to pull out all the stops to build up its presence stateside.
After resisting a bidfrom Valeant, ISTA went to Bausch & Lomb for 40% more.
Bausch & Lomb's willingness to shell out $500 million has a lot to do with ISTA's pipeline of experimental therapies.
So what if Valeant Pharmaceuticals wasn't able to pull off its bid for ISTA Pharmaceuticals? It's snapping up Eyetech instead. The Canadian drugmaker ($VRX) agreed to pay "significantly less than two
Valeant Pharmaceuticals CEO Michael Pearson has walked away from another deal. The Canadian drugmaker withdrew its $7.50-per-share bid to acquire ISTA Pharmaceuticals, one day ahead of its official
Whether Valeant Pharmaceuticals' ($VRX) latest news is good or bad depends upon your point of view. If you're an investor or analyst, it's good: The company forecast estimate-beating earnings and
Well, that was quick. Executives at ISTA Pharmaceuticals ($ISTA) have mulled over Valeant Pharmaceutical's ($VRX) $327 million unsolicited initial bid for the company, and found it lacking. (Valeant
Canada's Valeant Pharmaceuticals ($VRX) will push for at least one more acquisition before the holidays: U.S.-based rival ISTA Pharmaceuticals ($ISTA). The unsolicited bid for the California-based